Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.

Abstract

Hereditary breast cancer syndromes are associated with an increased risk of breast cancer and constitute a unique patient population, making up approximately 5%-10% of breast cancer cases in the United States. By virtue of the germline mutations that define these syndromes, invasive breast cancers in these patients have unique mechanisms that can be rationally targeted for therapeutic opportunities distinct from standard of care treatments in nongermline mutation associated breast cancers. This review intends to describe existing data on several of the most common hereditary breast cancer syndromes, including BRCA-related breast cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome, Peutz-Jeghers syndrome, and hereditary diffuse gastric cancer syndrome, specifically focusing on rational therapeutics utilized in these distinct patient subgroups and completed or ongoing clinical trials evaluating their efficacy. By exploiting the distinct biologic features associated with these syndromes, tailored treatment strategies have the potential for improved efficacy and lower toxicity. Knowledge of the emergence of these targeted cancer therapies is critical for appropriate management in these patients, extending beyond treatment to highlight the need for appropriate genetic screening to allow for early recognition of these patients and therefore appropriate treatment.

IMPLICATIONS FOR PRACTICE:

Molecular testing allows for identification of germline mutations that place individuals at high risk for breast cancer and that are associated with distinct histopathology and molecular characteristics that define the invasive breast cancer cases that these patients develop. These unique characteristics may ultimately provide rational targets for systemic treatments with improvements in both morbidity and efficacy. Identification of patients with these germline mutations is important for not only appropriate screening and prophylaxis, but knowledge of therapies specifically targeting several of the most common hereditary breast cancer syndromes is essential to ensure appropriate treatment of invasive breast cancers in these patients.

• Authors: Amanda Parkes, Banu K Arun, Jennifer K Litton
• Journal: The oncologist (Oncologist) Vol. 22 Issue 6 Pg. 655-666 (06 2017) ISSN: 1549-490X [Electronic] England
• PMID: 28469042 (Publication Type: Journal Article, Review)
• Copyright: © AlphaMed Press 2017.

Topics

• Breast Neoplasms (epidemiology, genetics, pathology, therapy)
• Female
• Genetic Predisposition to Disease
• Genetic Testing
• Germ-Line Mutation (genetics)
• Humans
• Mutation
• Neoplastic Syndromes, Hereditary (epidemiology, genetics, pathology, therapy)
• United States (epidemiology)